Asthma care has undergone significant changes in recent years. Traditional reliance on short acting beta agonist inhalers, commonly known as blue inhalers, is increasingly being replaced by approaches that also address the underlying airway inflammation responsible for asthma symptoms.
Recent data show that more patients are now using combination inhalers than relying solely on blue reliever inhalers. This represents a major shift in asthma management and aligns with updated national guidance developed jointly by NICE, the British Thoracic Society and the Scottish Intercollegiate Guidelines Network.
The rationale is straightforward. While blue inhalers provide rapid symptom relief, they do not treat airway inflammation. Over reliance on reliever inhalers may mask worsening asthma control and can increase the risk of severe exacerbations.
Combination inhalers provide symptom relief while simultaneously treating inflammation. Evidence suggests that this approach can reduce exacerbations, improve control and reduce healthcare utilisation.
For primary care, annual asthma reviews remain essential. They provide opportunities to assess inhaler technique, review medication adherence, evaluate symptom control and discuss personalised asthma action plans.
Further Reading
NICE Asthma Guidance
British Thoracic Society Asthma Guidelines
NHS Asthma Information
Recent Comments